Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells

Journal of biomedical science

Volumn 9, Issue 6, 2002, Pages 665-674

  Liu, Young Chau ^b,d   Leu, Chuen Miin ^b   Wong, Fen Hwa ^c   Fong, Wan Shung ^a   Chen, Shan Chun ^b   Chang, Chungming ^a,b   Hu, Cheng po ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Institute of Microbiology and Immunology   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d SHU TE UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL CULTURE; CELL DIVISION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; ESOPHAGUS TUMOR; HUMAN; MOUSE; MOUSE MUTANT; PHOSPHORYLATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOCRINE COMMUNICATION; CELL DIVISION; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, SCID; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 1842847423     PISSN: 10217770     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02254995     Document Type: Article

References (33)

1. Baserga R. The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 55:249-252; 1995.
2. Baserga R. Controlling IGF-receptor function: A possible strategy for tumor therapy. Trends Biotechnol 14:150-152; 1996.
3. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 253:1-6; 1999.
4. Blot WL Esophageal cancer trends and risk factors. Semin Oncol 21: 403-410; 1994.
5. Chert S, Chou C, Wong F, Chang C, Hu C. Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and auto-crine stimulation in human esophageal carcinoma cells. Cancer Res 51:1898-1903; 1991.
6. DeCamp MM Jr, Swanson S J, Jaklitsch MT. Esophagectomy after induction chemoradiation. Chest 116(6 suppl):466S-469S; 1999.
7. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 57:2687-2693; 1997.
8. Enzinger DC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Onco126: 12-20; 1999.
9. Galiana C, Lozano LC, Bancel B, Nakazawa H, Yamasaki H. High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol Carcinog 14:286-293; 1995.
10. Gatzka M, Prisco M, Baserga R. Stabilization of the Ras oncoprotein by the insulin-like growth factor 1 receptor during anchorage-independent growth. Cancer Res 60:4222-4230; 2000.
11. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced ceil death -proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56:1-10; 1999.
12. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri H J, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378; 1999.
13. Hu C, Hsieh H, Chien K, Wang P, Wang C, Chen C, Lo S J, Wuu K, Chang C. Biologic properties of three newly established human esophageal carcinoma cell lines. J Natl Cancer Inst 72:577-583; 1984.
14. Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S, Miyata M, Oka H, Doki Y, Mori T. Prognostic significance of transforming growth factor-α in human esophageal carcinoma. Cancer 71: 2902-2909; 1993.
15. Leu C, Chang C, Hu C. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 19:1665-1675; 2000.
16. Li W, Hyun T, Heller M, Yam A, Flechner L, Pierce JH, Rudikoff S. Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth. Cancer Res 60:3909-3915;2000.
17. Liu Y, Chen S, Chang C, Leu C, Hu C. Platelet-derived growth factor is an autocrine stimulator for the growth and survival of human esophageal carcinoma cell lines. Exp Cell Res 228:206-211;1996
18. Medgyesy DC, Wolff RA, Putnam JB Jr, Ajani JA. Small cell carcinoma of the esophagus: The University of Texas M.D. Anderson Cancer Center experience and literature review. Cancer 88:262-267; 2000.
19. Ota A, Wilson GL, Leroith D. Insulin-like growth factor I receptors on mouse neuroblas-toma cells. Two beta subunits are derived from differences in glycosylation. Eur J Biochem 174:521-530; 1988.
20. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19:7203-7215; 1999.
21. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53:1102-1106; 1993.
22. Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res 52: 6447-6451; 1992.
23. Romano G, Prisco M, Zanocco-Marani T, Peruzzi F, Valentinis B, Baserga R. Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. J Cell Biochem 72: 294-310; 1999.
24. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seeber S, Gabbert HE. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer 84:86-91; 1999.
25. Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 80:1366-1372; 1999.
26. Siewert JR, Roder JD. Lymphadenectomy in esophageal cancer surgery. Dis Esophagus 5: 91-97; 1992.
27. Steenbergh DH, Koonen-Reemst AMCB, Cleutjens CBJM, Sussenbach JS. Complete nucleotide sequence of the high molecular weight human IGF-I mRNA. Biochem Biophys Res Commun 175: 507-514; 1991.
28. Tso JY, Sun XH, Kao TH, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. Nucleic Acids Res 13:2485-2502; 1985.
29. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chert E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5:2503-2512; 1986.
30. Von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Senfferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60: 4573-4581; 2000.
31. Wong F, Hu C, Chiu J, Huang B, Chang J, Lin P, Chien K, Chang C. Expression of multiple oncogenes in human esophageal carcinomas. Cancer Invest 12:121-131; 1994.
32. Yoshida K, Kyo E, Tsuda T, Tsujino T, lto M, Nimoyo M, Tahara E. EGF and TGFα, the ligands of hyperproduced EGFR in human esophageal carcinoma cells, act as autocrine growth factors. Int J Cancer 45: 131-135; 1990.
33. Zhou P, Jiang W, Zhang Y, Kahn SM, Schieren I, Santella RM, Weinstein IB. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11: 571-580; 1995.